References
- Research C for DE and FDA grants nivolumab accelerated approval for third-line treatment of metastatic small cell lung cancer. FDA. [Published online 2019 Feb 9; cited 2020 May 5]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-nivolumab-accelerated-approval-third-line-treatment-metastatic-small-cell-lung-cancer
- Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883–895.
- Ready N, Farago AF, de Braud F, et al. Third-line nivolumab monotherapy in recurrent SCLC: CheckMate 032. J Thorac Oncol. 2019;14(2):237–244.
- Antonia SJ, Borghaei H, Ramalingam SS, et al. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol. 2019;20(10):1395–1408.
- Estimating the long-term outcomes associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations. ISPOR | International Society For Pharmacoeconomics and Outcomes Research. [cited 2020 May 5]. https://www.ispor.org/publications/journals/value-outcomes-spotlight/abstract/january-february-2018/estimating-the-long-term-outcomes-associated-with-immuno-oncology-therapies-challenges-and-approaches-for-overall-survival-extrapolations.
- Sanders GD, Neumann PJ, Basu A, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093–1103.
- Eckardt JR, von Pawel J, Pujol J-L, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25(15):2086–2092.
- SEER Cancer Statistics Review, 1975-2017. SEER. [cited 2020 May 5]. https://seer.cancer.gov/csr/1975_2017/index.html
- National Comprehensive Cancer Network. Clinical practice guidelines in non-small cell lung cancer, Version 1.2020. [cited 2019 Dec 10]. Available from: https://www.Nccn.Org/Professionals/Physician_gls/Pdf/Nscl.Pdf.
- Othus M, Bansal A, Koepl L, et al. Accounting for cured patients in cost-effectiveness analysis. Value Health. 2017;20(4):705–709.
- Ramsey SD, Othus M, Roth JA, et al. PRM126 – A COMPARISON OF MIXTURE CURE AND STANDARD PARAMETRIC MODELING TO ESTIMATE LONG-TERM SURVIVAL FOR SMALL-CELL LUNG CANCER IN PATIENTS TREATED WITH NIVOLUMAB AFTER PROGRESSION. Value Health. 2018;21:S377.
- Healthcare Cost and Utilization Project (HCUP). [cited 2020 May 5]. http://www.ahrq.gov/data/hcup/index.html.
- Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117–128.
- Decision Modelling for Health Economic Evaluation – Health Economics Research Centre (HERC). [cited 2020 May 5]. https://www.herc.ox.ac.uk/downloads/decision-modelling-for-health-economic-evaluation.
- Smare C, Dave K, Juarez-Garcia A, et al. PCN227 A PARTITIONED SURVIVAL MODEL TO DETERMINE COST-EFFECTIVENESS OF THIRD-LINE NIVOLUMAB MONOTHERAPY FOR SMALL CELL LUNG CANCER. Value in Health. 2019;22:S480.